Statins may help prolong survival in NSCLC resection

Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins.

Researchers from Northwestern University Feinberg School of Medicine, Chicago, and Penn State Hershey Cancer Institute followed 803 patients who underwent resection for , of which 315 were using statins.

Results showed that statin use was associated with a significantly lower local recurrence rate and significantly higher overall survival compared with non-statin users.

Researchers conclude that prospective studies are needed to assess the role of statin therapy as an adjunct to current multimodality regimens.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Study finds no link between statins and cancer risk

Jul 25, 2011

(Medical Xpress) -- A new study published in the Journal of the American College of Cardiology reports that, contrary to previous studies, the use of cholesterol reducing statin drugs does not increase the risk of patien ...

Recommended for you

Physicians target the genes of lung, colon cancers

9 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

User comments